Actively Recruiting
Open-Label Trial Evaluating Safety and Efficacy of GEN1119 in Adults with Solid Tumors
Led by Genmab · Updated on 2026-10-06
112
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and antitumor activity of GEN1119 in participants with certain types of solid tumors in this first-in-human, open-label Phase 1 trial. The study aims to find the best dose of GEN1119 and assess how well it works in treating these cancers. This trial is sponsored by Genmab and involves multiple parts to test different doses and refine the treatment approach. Participants will receive GEN1119 at various dose levels depending on the trial phase. The trial includes three parts initial dose escalation to determine safety and optimal doses, dose refinement to further define the best dose, and an expansion phase where participants receive GEN1119 at the recommended dose. All participants receive the active drug, with no placebo group. Administration schedules and dose levels vary as the study progresses. The trial lasts about 18 months for each participant, including up to 21 days of screening, around 5 months of treatment, and approximately 12.5 months of follow-up. Participants will visit the study site frequently during the first 6 weeks of treatment, then less often afterward. During visits, tests such as blood draws, heart activity monitoring, and CT scans will be performed to assess safety and treatment effects. Researchers will monitor dose-limiting toxicities, adverse events, and tumor response rates throughout the trial.
CONDITIONS
Brief Title
A Phase 1 Trial of GEN1119 in Participants With Solid Tumors
Research Team
G
Genmab Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here